Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 8-K (Current Report)
Date: June 17, 2025
Event: Announcement of positive topline data from the Phase 2 Explore-CKD clinical trial evaluating lorundrostat (25 mg) in subjects with hypertension and comorbid chronic kidney disease (CKD).
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial results. It does not contain financial statements, revenue, profit, cash flow, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Results
The filing details statistically significant and clinically meaningful results from the Explore-CKD trial (N=59), a randomized, double-blind, placebo-controlled crossover study. Key findings include:
- Systolic Blood Pressure (Primary Endpoint): Placebo-adjusted reduction of -7.5 mmHg (p=0.0024).
- Urine Albumin-to-Creatinine Ratio (UACR): Placebo-adjusted reduction of -25.60% (p=0.0015), suggesting potential renal protective effects.
- Estimated Glomerular Filtration Rate (eGFR): Placebo-adjusted decrease of -4.58% (p=0.0362). Management notes this is consistent with other renin-angiotensin-aldosterone pathway inhibitors and results from reduced glomerular over-perfusion.
- Safety Profile:
- Treatment-emergent adverse events (TEAEs) leading to discontinuation: 3% (lorundrostat) vs. 2% (placebo).
- Confirmed hyperkalemia (K+ >6.0 mmol/L): 5% (lorundrostat) vs. 0% (placebo).
- Serious adverse events: 3% (lorundrostat) vs. 0% (placebo).
Outlook, Management Commentary, and Risks
Management Commentary: The results support the efficacy and safety of aldosterone synthase inhibitors in addressing hypertension mechanisms in patients with compromised renal function. The company views the UACR reduction as consistent with renal protective potential.
Pipeline Context:
- Completed: Phase 3 Launch-HTN, Phase 2 Advance-HTN, and Phase 2 Target-HTN trials for uncontrolled/resistant hypertension.
- Ongoing: Transform-HTN (open-label extension for long-term efficacy/safety) and Explore-OSA (initiated Q1 2025 for OSA and uncontrolled hypertension).
Risks and Contingencies:
- Observed reduction in eGFR, though anticipated for this drug class, requires monitoring.
- Incidence of hyperkalemia and serious adverse events, though low, presents a safety consideration.
- Future clinical outcomes and regulatory approval remain contingent on further data and review.
Investor Verification Checklist
- Verify the full statistical analysis plan and detailed safety data in the attached press release (Exhibit 99.1).
- Confirm the timeline for regulatory filings or Phase 3 trial initiation based on these Phase 2 results.
- Review the company's cash runway and capital requirements, as this filing does not disclose financial status.
- Assess the competitive landscape for aldosterone synthase inhibitors in the CKD and hypertension markets.
- Monitor upcoming data releases from the Transform-HTN and Explore-OSA trials.